Immune mediated inflammatory diseases (IMIDs) are diseases in which our immune system is defective and causes chronic tissue damage. The consortium partners hypothesize that a faulty immune response to intestinal bacteria is an important driver of disease in these patients. In this partnership of six academic institutions and five companies, the researchers will unravel the common cellular basis for seven IMIDs. They will analyze the deregulated anti-microbial immune response and classify these IMIDs on the basis of this immune response. These results will empower more precise treatments using existing drugs and identify new targets for future drug development.
The consortium aims to improve treatment of IMID in the near future by realizing precision medicine geared at treating the patients’ individual disease as effectively as possible with as few side effects as possible.